Tumor Treatment Field Therapy (TTFT)
L34823
Tumor treating field therapy (HCPCS E0766) is covered only for newly diagnosed, histologically confirmed supratentorial glioblastoma (WHO grade IV astrocytoma) after maximal debulking when feasible and following chemoradiotherapy, with initiation within 7 weeks of the last concurrent chemo/radiotherapy dose, no progression by RANO, KPS ≥70, and planned use averaging 18 hours per day. Continued coverage beyond the initial three months requires an in‑person treating practitioner re‑evaluation between day 60 and day 91 documenting objective adherence and clinical benefit; TTFT is denied for recurrent GBM and for indications other than newly diagnosed GBM. Claims must meet documentation (histology, treatment records, KPS, SWO/WOPD, POD, re‑evaluation notes) and coding requirements or they will be denied.
"Tumor treating field therapy (HCPCS E0766) is covered for newly diagnosed, histologically confirmed WHO grade IV astrocytoma (glioblastoma multiforme) that is supratentorial."